Readjudication

$title =

Zodasiran – RNA interference (RNAi) therapy targeting expression of ANGPTL3 in the liver.

;

$content = [

via Arrowhead pharmaceuticals

mixed hyperlipidemia (fasting triglyceride level of 150 to 499 mg per deciliter and either an LDL cholesterol level of ≥70 mg per deciliter or a non-HDL cholesterol level of ≥100 mg per deciliter).

zodasiran (50, 100, or 200 mg) or placebo on day 1 and week 12 and were followed through week 36. The primary end point was the percent change in the triglyceride level from baseline to week 24.

significant dose-dependent decreases in triglyceride levels were observed difference in change vs. placebo:

50: −51 percentage points

100: −57 percentage points

200: −63 percentage points

(P<0.001 for all comparisons)

 LDL cholesterol level

−16 percentage points

−14 percentage points

−20 percentage points, respectively.

];

$date =

;

$category =

;

$author =

Anthony Taylor

;

$previous =

;

$next =

;